Global Benign Prostatic Hyperplasia Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Therapeutic Class;

Alpha Blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase 5 Inhibitor, and Others.

By Therapy;

Mono Drug Therapy and Combination Drug Therapy.

By Geography;

North America, Europe, Asia Pacific, Middle East and Africa, and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn248389889 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Benign Prostatic Hyperplasia Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Benign Prostatic Hyperplasia Therapeutics Market was valued at USD 7,187.23 million. The size of this market is expected to increase to USD 9,560.23 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 4.2%.

The Global Benign Prostatic Hyperplasia (BPH) Therapeutics Market is expanding as the prevalence of BPH increases with the aging male population. BPH, characterized by prostate enlargement, leads to urinary symptoms that can significantly affect a patient's quality of life. As the global male population over 50 grows, the demand for effective therapeutic treatments for BPH is rising. The market is driven by advancements in medical treatments, including both drug-based therapies and surgical interventions, with a significant focus on pharmacological treatments for symptom management.

The market is segmented by therapy into Mono Drug Therapy and Combination Drug Therapy. Mono Drug Therapy includes treatments such as alpha-blockers and 5-alpha reductase inhibitors, which are often used to alleviate symptoms like urinary frequency and difficulty. These treatments are well-established and commonly prescribed for mild to moderate cases of BPH. However, in more severe cases or when mono therapy is insufficient, Combination Drug Therapy is used, which combines different classes of drugs like alpha-blockers with 5-alpha reductase inhibitors or phosphodiesterase-5 inhibitors. Combination therapy aims to address both symptom relief and long-term reduction in prostate size, offering more comprehensive treatment for patients.

Geographically, the North American and European markets are the largest due to advanced healthcare infrastructures, high healthcare spending, and an aging population. Meanwhile, Asia-Pacific is emerging as a key growth region, driven by increasing healthcare awareness and expanding access to medical treatments. The market is also seeing significant innovation, with newer drug formulations and treatments being introduced to improve patient outcomes. Overall, the Benign Prostatic Hyperplasia Therapeutics Market is poised for growth, with continued research and development expected to enhance treatment options and address the evolving needs of the global BPH patient population.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Therapeutic Class
    2. Market Snapshot, By Therapy
    3. Market Snapshot, By Region
  4. Global Benign Prostatic Hyperplasia Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Aging Population
        2. Increasing BPH Prevalence
        3. Rising Awareness
        4. Favorable Reimbursement
        5. Demand for Minimally Invasive Procedures
      2. Restraints
        1. Side Effects of Therapies
        2. Limited Healthcare Access
        3. Cultural Stigmas
        4. Regulatory Hurdles
        5. Patent Expirations
      3. Opportunities
        1. Novel Therapeutics Development
        2. Digital Health Integration
        3. Patient Education
        4. Value-Based Healthcare Models
        5. Biomarker Research
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry
  5. Market Segmentation
    1. Global Benign Prostatic Hyperplasia Therapeutics Market, By Therapeutic Class, 2021 - 2031 (USD Million)
      1. Alpha Blockers
      2. 5-Alpha Reductase Inhibitors
      3. Phosphodiesterase 5 Inhibitor
      4. Others
    2. Global Benign Prostatic Hyperplasia Therapeutics Market, By Therapy, 2021 - 2031 (USD Million)
      1. Mono Drug Therapy
      2. Combination Drug Therapy
    3. Global Benign Prostatic Hyperplasia Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. Karl Storz
      2. Boston Scientific Corporation
      3. Olympus America
      4. Endo Pharmaceuticals Inc.
      5. biolitec AG
      6. Medifocus
      7. Cook Medical
      8. Teleflex Incorporated
      9. Urotronic
      10. Coloplast Corp
      11. Richard Wolf GmbH
      12. PROCEPT BioRobotics Corporation
  7. Analyst Views
  8. Future Outlook of the Market